MODEST GROWTH FOR CIBA-GEIGY ITALIA

12 April 1992

Ciba-Geigy's Italian subsidiary achieved a modest increase for 1991 to 1,063 billion lire ($866.5 million), while profits climbed to 20 billion lire ($16.3 million).

According to Pier Alfonso Borney, director general of Ciba-Geigy Italia, the subsidiary is showing a 3% rise in sales in the early months of 1992, helped by foreign exchange factors. The group's Italian performance reflects in particular a 10% rise in its agricultural division's sales, according to Mr Borney.

Investments trebled last year to 112.3 billion lire, with that figure including work at the new unit at Torre Annunziata which is now 65% complete. Earlier this year, under a joint venture with Chiron of the USA (Marketletter January 1 & 6), the Swiss parent company completed the takeover of the vaccine operations of the Italian Sclavo group.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight